Physician profile
Donna Lam
NPI 1760244719
$13,379.48
in general payments reported to CMS, 2019-2025
24 companies · $9,884 in 2025
The $9,884 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $3,496 · 2025: $9,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,344 · Travel and Lodging: $2,473 · Consulting Fee: $2,364 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,343.67 |
| Travel and Lodging | $2,473.07 |
| Consulting Fee | $2,363.75 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $5,045.44 | 2024-2025 | Zoryve |
| Leo Pharma INC. | $1,661.05 | 2024-2025 | Adbry, Anzupgo, Spevigo |
| Incyte Corporation | $930.43 | 2024-2025 | Opzelura |
| Abbvie INC. | $685.00 | 2024-2025 | |
| Galderma Laboratories, L.P. | $662.16 | 2024-2025 | Nemluvio, Aklief, Dysport |
| Dermavant Sciences, INC. | $627.72 | 2024 | Vtama |
| Genzyme Corporation | $501.22 | 2024-2025 | |
| Pfizer INC. | $434.99 | 2024-2025 | |
| Amgen INC. | $422.77 | 2024-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $323.39 | 2024-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $316.06 | 2024-2025 | |
| Lilly USA, LLC | $280.52 | 2024-2025 | Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $217.08 | 2024 | Sotyktu |
| Ucb, INC. | $202.82 | 2024-2025 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $198.99 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $164.28 | 2024 | |
| Journey Medical Corporation | $151.43 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $148.06 | 2024-2025 | Cabtreo, Jublia, Siliq |
| Regeneron Healthcare Solutions, INC. | $140.31 | 2024-2025 | Dupixent, Libtayo |
| Organon LLC | $115.13 | 2025 | Vtama |
| Biofrontera INC. | $75.59 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Solta Medical, A Division of Bausch Health US, LLC | $41.59 | 2025 | |
| Botanix Sb INC | $19.07 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $14.38 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.